AU2018268087B2 - Compositions and methods for cell targeting therapies - Google Patents

Compositions and methods for cell targeting therapies Download PDF

Info

Publication number
AU2018268087B2
AU2018268087B2 AU2018268087A AU2018268087A AU2018268087B2 AU 2018268087 B2 AU2018268087 B2 AU 2018268087B2 AU 2018268087 A AU2018268087 A AU 2018268087A AU 2018268087 A AU2018268087 A AU 2018268087A AU 2018268087 B2 AU2018268087 B2 AU 2018268087B2
Authority
AU
Australia
Prior art keywords
cells
cell
rhob
tcr
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2018268087A
Other languages
English (en)
Other versions
AU2018268087A1 (en
Inventor
Dennis BERINGER
Jürgen Herbert Ernst KUBALL
Zsolt SEBESTYEN
Anna VYBOROVA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UMC Utrecht Holding BV
Original Assignee
UMC Utrecht Holding BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UMC Utrecht Holding BV filed Critical UMC Utrecht Holding BV
Publication of AU2018268087A1 publication Critical patent/AU2018268087A1/en
Application granted granted Critical
Publication of AU2018268087B2 publication Critical patent/AU2018268087B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4253—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2018268087A 2017-05-18 2018-05-18 Compositions and methods for cell targeting therapies Ceased AU2018268087B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762508272P 2017-05-18 2017-05-18
US62/508,272 2017-05-18
US201762508833P 2017-05-19 2017-05-19
US62/508,833 2017-05-19
PCT/EP2018/063210 WO2018211115A1 (en) 2017-05-18 2018-05-18 Compositions and methods for cell targeting therapies

Publications (2)

Publication Number Publication Date
AU2018268087A1 AU2018268087A1 (en) 2020-01-02
AU2018268087B2 true AU2018268087B2 (en) 2022-03-17

Family

ID=62492593

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018268087A Ceased AU2018268087B2 (en) 2017-05-18 2018-05-18 Compositions and methods for cell targeting therapies

Country Status (7)

Country Link
US (1) US12161669B2 (https=)
EP (1) EP3624823A1 (https=)
JP (1) JP7486953B2 (https=)
CN (1) CN110944658A (https=)
AU (1) AU2018268087B2 (https=)
CA (1) CA3063807A1 (https=)
WO (1) WO2018211115A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2831109B1 (en) 2012-03-28 2017-12-06 Gadeta B.V. Combinatorial gamma 9 delta 2 t cell receptor chain exchange
JP2019525898A (ja) 2016-06-10 2019-09-12 ガデタ・ベー・フェー ヒト白血球抗原拘束ガンマデルタｔ細胞受容体及びその使用方法
JP7486953B2 (ja) 2017-05-18 2024-05-20 ユーエムセー・ユトレヒト・ホールディング・ベー・フェー 細胞標的化療法のための組成物および方法
WO2019156566A1 (en) * 2018-02-12 2019-08-15 Umc Utrecht Holding B.V. Bispecific molecules comprising gamma-delta tcr and t-cell or nk cell binding domain
WO2019219979A1 (en) * 2018-05-18 2019-11-21 Umc Utrecht Holding B.V. Compositions and methods for cell targeting therapies
CN112255395B (zh) * 2020-12-23 2021-06-18 中生北控生物科技股份有限公司 一种消除脂血样本中乳糜干扰的方法和免疫浊度法试剂盒及应用
WO2022136681A1 (en) 2020-12-23 2022-06-30 Gadeta B.V. Chimeric, transmembrane proteins with bidirectional signalling activity
US20240115705A1 (en) * 2021-02-08 2024-04-11 The J. Gladstone Institutes, a testamentary trust established under the will of J. David Gladstone Regulation of Butyrophilin subfamily 3 member A1 (BTN3A1, CD277)
KR20230159851A (ko) * 2021-03-22 2023-11-22 주노 쎄러퓨티크스 인코퍼레이티드 치료 세포 조성물의 효력을 결정하는 방법
WO2022214707A1 (en) 2021-04-09 2022-10-13 Gadeta B.V. Cellular reporter and methods of using the same
US20260014199A1 (en) 2022-06-17 2026-01-15 Gadeta B.V. Modified immune cells
GB202406837D0 (en) * 2024-05-14 2024-06-26 Immunocore Ltd Screening methods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090105133A1 (en) * 2004-11-23 2009-04-23 Medigene Limited Gamma-Delta T Cell Receptors
US20150353643A1 (en) * 2013-09-24 2015-12-10 Universite De La Mediterranee - Aix-Marseille Ii Anti-cd277 antibodies and uses thereof

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5260223A (en) 1986-07-03 1993-11-09 President & Fellows Of Harvard College Methods for detection of human gamma, γ T cell receptor
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
CA2096222C (en) 1990-11-13 1998-12-29 Stephen D. Lupton Bifunctional selectable fusion genes
FR2698880B1 (fr) 1992-11-25 1995-02-24 Inst Nat Sante Rech Med Procédé de production de récepteurs T solubles, produits ainsi obtenus et leur utilisation dans des compositions diagnostiques ou thérapeutiques.
WO1994028143A1 (en) 1993-05-21 1994-12-08 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US5885827A (en) 1996-01-23 1999-03-23 The Regents Of The Universtiy Of California Eukaryotic high rate mutagenesis system
US6207455B1 (en) 1997-05-01 2001-03-27 Lung-Ji Chang Lentiviral vectors
JP4390860B2 (ja) 1997-05-13 2009-12-24 ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル レンチウイルスをベースにした遺伝子転移ベクター
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6218181B1 (en) 1998-03-18 2001-04-17 The Salk Institute For Biological Studies Retroviral packaging cell line
GB9810099D0 (en) 1998-05-11 1998-07-08 Isis Innovation Novel molecule and diagnostic method
WO1999060120A2 (en) 1998-05-19 1999-11-25 Avidex Limited Soluble t cell receptor
DE19909769A1 (de) 1999-03-05 2000-09-07 Bundesrepublik Deutschland Let Von SIVagm abgeleitete lentivirale Vektoren, Verfahren zu ihrer Herstellung und ihre Verwendung zur Genübertragung in Säugerzellen
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
CA2406864A1 (en) 2000-02-24 2001-08-30 Life Technologies Corporation Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
JP2001332430A (ja) 2000-05-22 2001-11-30 Murata Mfg Co Ltd トランス
US20030031678A1 (en) 2000-09-19 2003-02-13 Shujath Ali Compositions and methods relating to prostate specific genes and proteins
CN1280307C (zh) 2001-04-03 2006-10-18 宝生物工程株式会社 细胞毒性t淋巴细胞
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
WO2004016225A2 (en) 2002-08-19 2004-02-26 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2003060097A2 (en) 2002-01-10 2003-07-24 National Jewish Medical And Research Center USE OF SOLUBLE Ϝδ T CELL RECEPTORS FOR REGULATING T CELL FUNCTION
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
US7892745B2 (en) 2003-04-24 2011-02-22 Xdx, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
JP4516916B2 (ja) 2003-07-11 2010-08-04 昇志 佐藤 リビン由来のｈｌａ−ａ２４結合性癌抗原ペプチド
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US8361794B2 (en) 2004-06-29 2013-01-29 Immunocore Limited Cells expressing a modified T cell receptor
GB0506760D0 (en) 2005-04-01 2005-05-11 Avidex Ltd High affinity HIV TCRS
EP1941028A2 (en) 2005-08-08 2008-07-09 Fondazione Centro San Raffaele Del Monte Tabor Use of common gamma chain cytokines for the visualization, isolation and genetic modification of memory t lymphocytes.
US20080131415A1 (en) 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
BRPI0807952A2 (pt) 2007-02-20 2014-06-10 Anaptysbio Inc Sistemas de hipermutação somática
ES2622505T3 (es) 2008-05-09 2017-07-06 Agency For Science, Technology And Research Receptor de linfocito T (RLT) exógeno reactivo contra epítopo de VHB y usos del mismo
CN102272153B (zh) 2008-11-24 2015-04-15 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 高亲和力t细胞受体及其应用
WO2010087335A1 (ja) 2009-01-27 2010-08-05 学校法人産業医科大学 Ｔ細胞抗原受容体遺伝子、受容体α鎖及びβ鎖発現用ベクター並びに細胞障害性Ｔ細胞
EP2496244B8 (en) 2009-11-02 2017-11-22 Emory University Drug resistant immunotherapy for treatment of a cancer
CN102453701B (zh) 2010-10-26 2014-08-13 中国医学科学院基础医学研究所 基因修饰CDR3δ移植型γδT淋巴细胞及其抑癌用途
ES2588730T3 (es) 2011-03-17 2016-11-04 Miltenyi Biotec Gmbh Preparados celulares agotados en lo que respecta a TCRalfa/beta
CN102532269B (zh) 2011-05-16 2014-07-09 中国医学科学院基础医学研究所 γδT淋巴细胞中δ1链互补决定域3的优势序列及其TCR受体转染细胞与应用
CN103635573B (zh) 2011-05-19 2016-05-11 分子医学研究所 包含γδT细胞的淋巴细胞系、其组合物及生产方法
EP3549611B1 (en) 2011-07-29 2021-06-30 The Trustees of the University of Pennsylvania Switch costimulatory receptors
EP2831109B1 (en) 2012-03-28 2017-12-06 Gadeta B.V. Combinatorial gamma 9 delta 2 t cell receptor chain exchange
EP2906684B8 (en) 2012-10-10 2020-09-02 Sangamo Therapeutics, Inc. T cell modifying compounds and uses thereof
US20150259645A1 (en) 2012-11-08 2015-09-17 INSERM (Institut National de la Santé et de la Recherche Médicale Method for inducing il-2-free proliferation of gamma delta t cells
WO2014179202A1 (en) 2013-05-02 2014-11-06 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosis of celiac disease
WO2015063069A1 (en) 2013-10-28 2015-05-07 Benjamin Felder Chimeric antigen receptors with antigen binding domains derived from gamma delta t cell receptors
CN106103711A (zh) 2013-11-21 2016-11-09 组库创世纪株式会社 T细胞受体和b细胞受体库分析系统及其在治疗和诊断中的应用
JP2017505819A (ja) 2014-02-04 2017-02-23 カイト ファーマ インコーポレイテッドＫｉｔｅ Ｐｈａｒｍａ， Ｉｎｃ Ｂ細胞悪性腫瘍及び他のがんの治療に有用な自己ｔ細胞を産生する方法、並びにその組成物
EP3144388B1 (en) 2014-05-13 2020-07-01 Chugai Seiyaku Kabushiki Kaisha T cell-redirecting antigen-binding molecule for cells having immunosuppression function
GB201506423D0 (en) 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
US10280188B2 (en) 2015-02-02 2019-05-07 Nagasaki University Fluorine-containing bisphosphonic acid derivative and use thereof
WO2016195086A1 (ja) 2015-06-05 2016-12-08 医療法人社団 滉志会 アレルギー性疾患の治療薬
PT3328894T (pt) 2015-08-06 2019-02-13 Agency Science Tech & Res Anticorpos de cadeia comum gama/il2rbeta
JP2018531593A (ja) 2015-09-11 2018-11-01 アジェナス インコーポレイテッド 操作された宿主細胞及びそれらの使用方法
CN105296431B (zh) 2015-11-26 2018-10-09 北京佳德和细胞治疗技术有限公司 肿瘤结合特异性γδTCR基因修饰的αβT细胞及其抑癌用途
US12297427B2 (en) 2015-12-04 2025-05-13 St. Jude Children's Research Hospital, Inc. Cloning and expression system for T-cell receptors
EP3454870A4 (en) * 2016-05-12 2020-03-04 Adicet Bio Inc. METHOD FOR SELECTIVE EXPANSION OF GAMMA DELTA T CELL POPULATIONS AND COMPOSITIONS THEREOF
JP2019525898A (ja) 2016-06-10 2019-09-12 ガデタ・ベー・フェー ヒト白血球抗原拘束ガンマデルタｔ細胞受容体及びその使用方法
WO2018162563A1 (en) 2017-03-07 2018-09-13 Universität Basel Mr1 restricted t cell receptors for cancer immunotherapy
JP7486953B2 (ja) 2017-05-18 2024-05-20 ユーエムセー・ユトレヒト・ホールディング・ベー・フェー 細胞標的化療法のための組成物および方法
WO2019156566A1 (en) 2018-02-12 2019-08-15 Umc Utrecht Holding B.V. Bispecific molecules comprising gamma-delta tcr and t-cell or nk cell binding domain
WO2019219979A1 (en) 2018-05-18 2019-11-21 Umc Utrecht Holding B.V. Compositions and methods for cell targeting therapies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090105133A1 (en) * 2004-11-23 2009-04-23 Medigene Limited Gamma-Delta T Cell Receptors
US20150353643A1 (en) * 2013-09-24 2015-12-10 Universite De La Mediterranee - Aix-Marseille Ii Anti-cd277 antibodies and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Sebestyen, Z. et al.; Cell Rep., 15, 1973-1985 (2016). DOI: 10.1016/j.celrep.2016.04.081. *

Also Published As

Publication number Publication date
JP2020520367A (ja) 2020-07-09
CA3063807A1 (en) 2018-11-22
EP3624823A1 (en) 2020-03-25
JP7486953B2 (ja) 2024-05-20
US12161669B2 (en) 2024-12-10
WO2018211115A1 (en) 2018-11-22
CN110944658A (zh) 2020-03-31
US20200368278A1 (en) 2020-11-26
AU2018268087A1 (en) 2020-01-02

Similar Documents

Publication Publication Date Title
AU2018268087B2 (en) Compositions and methods for cell targeting therapies
US12180517B2 (en) Expression of novel cell tags
US20240263183A1 (en) Modulating expression of polypeptides via new gene switch expression systems
CN109997041B (zh) 人白细胞抗原限制的γδT细胞受体及其使用方法
CN119569895A (zh) G蛋白偶合受体c类5族成员d(gprc5d)特异性嵌合抗原受体
WO2019219979A1 (en) Compositions and methods for cell targeting therapies
JP2024502479A (ja) キメラ受容体療法
RU2796334C9 (ru) Экспрессия новых клеточных меток
RU2796334C2 (ru) Экспрессия новых клеточных меток
KR20260051061A (ko) Cd19-표적화 car t 세포 요법
HK40111761A (zh) 嵌合受体疗法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired